Classical and paradoxical effects of TNF-α on bone homeostasis

Frontiers in Immunology

Volumn 5, Issue FEB, 2014, Pages

  Osta, Bilal ^a   Benedetti, Giulia ^a   Miossec, Pierre ^a  

^a University of Lyon   (France)

Author keywords

Ankylosing spondylitis; Bone homeostasis; Osteoblast; Osteoclast; Osteoporosis; Rheumatoid arthritis; TNF

Indexed keywords

ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; DICKKOPF RELATED PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PEPTIDES AND PROTEINS; PROTEIN KINASE B; PROTEIN P55; PROTEIN P75; SMAD UBIQUITINATION REGULATORY FACTOR 1; SOMATOMEDIN C; STAT PROTEIN; TMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1A; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT5A PROTEIN;

ANKYLOSING SPONDYLITIS; APOPTOSIS; BONE MASS; BONE REMODELING; BONE STRUCTURE; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CHRONIC ARTHRITIS; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84895524983     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00048     Document Type: Review

References (97)

1. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 3:745-56. doi:10.1038/nri1184.
2. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci (2008) 13:5094-107. doi:10.2741/3066.
3. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol (1992) 10:411-52. doi:10.1146/annurev.iy.10.040192.002211.
4. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385:729-33. doi:10.1038/385729a0.
5. MacEwan DJ. TNF ligands and receptors-a matter of life and death. Br J Pharmacol (2002) 135:855-75. doi:10.1038/sj.bjp.0704549.
6. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov (2010) 9:482-93. doi:10.1038/nrd3030.
7. Biton J, Boissier MC, Bessis N. TNFalpha: activator or inhibitor of regulatory T cells? Joint Bone Spine (2012) 79:119-23. doi:10.1016/j.jbspin.2011.09.017.
8. Danks L, Takayanagi H. Immunology and bone. J Biochem (2013) 154:29-39. doi:10.1093/jb/mvt049.
9. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev (2008) 223:7-19. doi:10.1111/j.1600-065X.2008.00626.x.
10. Feldmann M, Williams RO, Paleolog E. What have we learnt from targeted anti-TNF therapy? Ann Rheum Dis (2010) 69(Suppl 1):i97-9. doi:10.1136/ard.2009.117143.
11. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun (2010) 11:180-210. doi:10.1159/000289205.
12. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell (2007) 129:1081-95. doi:10.1016/j.cell.2007.03.055.
13. Klein-Nulend J, Bacabac RG, Bakker AD. Mechanical loading and how it affects bone cells: the role of the osteocyte cytoskeleton in maintaining our skeleton. Eur Cell Mater (2012) 24:278-91.
14. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, et al. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem (2012) 287:29851-60. doi:10.1074/jbc.M112.377945.
15. Vezeridis PS, Semeins CM, Chen Q, Klein-Nulend J. Osteocytes subjected to pulsating fluid flow regulate osteoblast proliferation and differentiation. Biochem Biophys Res Commun (2006) 348:1082-8. doi:10.1016/j.bbrc.2006.07.146.
16. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone (2007) 40:251-64. doi:10.1016/j.bone.2006.09.023.
17. Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, Paar C, et al. Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics (2007) 8:70. doi:10.1186/1471-2164-8-70.
18. Franz-Odendaal TA, Hall BK, Witten PE. Buried alive: how osteoblasts become osteocytes. Dev Dyn (2006) 235:176-90. doi:10.1002/dvdy.20603.
19. Schaffler MB, Kennedy OD. Osteocyte signaling in bone. Curr Osteoporos Rep (2012) 10:118-25. doi:10.1007/s11914-012-0105-4.
20. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone (2009) 45:1161-8. doi:10.1016/j.bone.2009.08.008.
21. Price C, Zhou X, Li W, Wang L. Real-time measurement of solute transport within the lacunar-canalicular system of mechanically loaded bone: direct evidence for load-induced fluid flow. J Bone Miner Res (2011) 26:277-85. doi:10.1002/jbmr.211.
22. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 17:1231-4. doi:10.1038/nm.2452.
23. Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab (2012) 23:582-90. doi:10.1016/j.tem.2012.05.005.
24. Abbas S, Zhang YH, Clohisy JC, Abu-Amer Y. Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine (2003) 22:33-41. doi:10.1016/S1043-4666(03)00106-6.
25. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology (2000) 141:3956-64. doi:10.1210/endo.141.11.7739.
26. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem (2002) 277:2695-701. doi:10.1074/jbc.M106339200.
27. Lee HL, Yi T, Baek K, Kwon A, Hwang HR, Qadir AS, et al. Tumor necrosis factor-alpha enhances the transcription of smad ubiquitination regulatory factor 1 in an activating protein-1-and Runx2-dependent manner. J Cell Physiol (2012) 228(5):1076-86. doi:10.1002/jcp.24256.
28. Zhao L, Huang J, Zhang H, Wang Y, Matesic LE, Takahata M, et al. Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells (2011) 29:1601-10. doi:10.1002/stem.703.
29. Ding J, Ghali O, Lencel P, Broux O, Chauveau C, Devedjian JC, et al. TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci (2009) 84:499-504. doi:10.1016/j.lfs.2009.01.013.
30. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab (2005) 288:E1011-8. doi:10.1152/ajpendo.00534.2004.
31. Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem (2006) 281:4326-33. doi:10.1074/jbc.M509430200.
32. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K. TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun (2007) 356:1004-10. doi:10.1016/j.bbrc.2007.03.099.
33. Yamazaki M, Fukushima H, Shin M, Katagiri T, Doi T, Takahashi T. Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB. J Biol Chem (2009) 284:35987-95. doi:10.1074/jbc.M109.070540.
34. Lee HL, Yi T, Woo KM, Ryoo HM, Kim GS, Baek JH. Msx2 mediates the inhibitory action of TNF-alpha on osteoblast differentiation. Exp Mol Med (2010) 42:437-45. doi:10.3858/emm.2010.42.6.045.
35. Lu X, Beck GR Jr, Gilbert LC, Camalier CE, Bateman NW, Hood BL. Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor alpha action in osteoblast differentiation. J Bone Miner Res (2011) 26:209-19. doi:10.1002/jbmr.203.
36. Lee HL, Yi T, Baek K, Kwon A, Hwang HR, Qadir AS. Tumor necrosis factor-alpha enhances the transcription of smad ubiquitination regulatory factor 1 in an activating protein-1-and Runx2-dependent manner. J Cell Physiol (2013) 228:1076-86. doi:10.1002/jcp.24256.
37. Sidney LE, Kirkham GR, Buttery L. Comparison of osteogenic differentiation of embryonic stem cells and primary osteoblasts, revealed by responses to IL-1beta, TNF-alpha and IFN-gamma. Stem Cells Dev (2014). doi:10.1089/scd.2013.0336.
38. Huang H, Zhao N, Xu X, Xu Y, Li S, Zhang J. Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells. Cell Prolif (2011) 44:420-7. doi:10.1111/j.1365-2184.2011.00769.x.
39. Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J. TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci U S A (2011) 108:1585-90. doi:10.1073/pnas.1018501108.
40. Hess K, Ushmorov A, Fiedler J, Brenner RE, Wirth T. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone (2009) 45:367-76. doi:10.1016/j.bone.2009.04.252.
41. Yu RY, Zeng BJ, Liu YS, Zhou YS. Recombinant human tumor necrosis factor-alpha promotes human adipose-derived stromal cells transforming into osteoblast in vitro. Beijing Da Xue Xue Bao (2012) 44:475-80. doi:10.3969/j.issn.1671-167X.2012.03.0.28.
42. Lu Z, Wang G, Dunstan CR, Zreiqat H. Short-term exposure to tumor necrosis factor-alpha enables human osteoblasts to direct adipose tissue-derived mesenchymal stem cells into osteogenic differentiation. Stem Cells Dev (2012) 21:2420-9. doi:10.1089/scd.2011.0589.
43. Cho HH, Shin KK, Kim YJ, Song JS, Kim JM, Bae YC, et al. NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. J Cell Physiol (2010) 223:168-77. doi:10.1002/jcp.22024.
44. Briolay A, Lencel P, Bessueille L, Caverzasio J, Buchet R, Magne D. Autocrine stimulation of osteoblast activity by Wnt5a in response to TNF-alpha in human mesenchymal stem cells. Biochem Biophys Res Commun (2013) 430:1072-7. doi:10.1016/j.bbrc.2012.12.036.
45. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D. Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 13:156-63. doi:10.1038/nm1538.
46. Mountziaris PM, Tzouanas SN, Mikos AG. Dose effect of tumor necrosis factor-alpha on in vitro osteogenic differentiation of mesenchymal stem cells on biodegradable polymeric microfiber scaffolds. Biomaterials (2010) 31:1666-75. doi:10.1016/j.biomaterials.2009.11.058.
47. Feng X, Feng G, Xing J, Shen B, Li L, Tan W. TNF-alpha triggers osteogenic differentiation of human dental pulp stem cells via the NF-kappaB signalling pathway. Cell Biol Int (2013) 37:1267-75. doi:10.1002/cbin.10141.
48. Bonewald LF. Osteoctytes. In: Marcus DFR, Nelson D, Rosen C editors. Osteoporosis, vol. 1, 3rd ed. San Diego: Elsevier (2007) p. 169-90.
49. Tan SD, Kuijpers-Jagtman AM, Semeins CM, Bronckers AL, Maltha JC, Von den Hoff JW. Fluid shear stress inhibits TNFalpha-induced osteocyte apoptosis. J Dent Res (2006) 85:905-9. doi:10.1177/154405910608501006.
50. Bakker AD, Silva VC, Krishnan R, Bacabac RG, Blaauboer ME, Lin YC. Tumor necrosis factor alpha and interleukin-1beta modulate calcium and nitric oxide signaling in mechanically stimulated osteocytes. Arthritis Rheum (2009) 60:3336-45. doi:10.1002/art.24920.
51. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res (1996) 11:1043-51. doi:10.1002/jbmr.5650110802.
52. Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol (2002) 198:220-7. doi:10.1002/path.1190.
53. Mucci JM, Scian R, De Francesco PN, Garcia FS, Ceci R, Fossati CA. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is medi-ated by T cells via TNF-alpha. Gene (2012) 509:51-9. doi:10.1016/j.gene.2012.07.071.
54. Matsubara R, Kukita T, Ichigi Y, Takigawa I, Qu PF, Funakubo N. Characterization and identification of subpopulations of mononuclear preosteoclasts induced by TNF-alpha in combination with TGF-beta in rats. PLoS One (2012) 7:e47930. doi:10.1371/journal.pone.0047930.
55. Kagiya T, Nakamura S. Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation. J Periodontal Res (2012) 48(3):373-85. doi:10.1111/jre.12017.
56. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) (2001) 79:243-53. doi:10.1007/s001090100226.
57. Horowitz MC, Xi Y, Wilson K, Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev (2001) 12:9-18. doi:10.1016/S1359-6101(00)00030-7.
58. Moon SJ, Ahn IE, Jung H, Yi H, Kim J, Kim Y. Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. Int J Mol Med (2013) 31:769-77. doi:10.3892/ijmm.2013.1269.
59. Miossec P, Chomarat P, Dechanet J, Moreau JF, Roux JP, Delmas P. Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum (1994) 37:1715-22. doi:10.1002/art.1780371202.
60. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum (2001) 44:1293-303. doi:10.1002/1529-0131(200106)44:6<::AID-ART221>3.0.CO;2-T.
61. Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddatz D, Munzel U. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res (2003) 18:529-38. doi:10.1359/jbmr.2003.18.3.529.
62. Lowik CW, Nibbering PH, van de Ruit M, Papapoulos SE. Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest (1994) 93:1465-72. doi:10.1172/JCI117124.
63. Kuratani T, Nagata K, Kukita T, Hotokebuchi T, Nakasima A, Iijima T. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol (1998) 13:751-9.
64. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum (2000) 43:821-6. doi:10.1002/1529-0131(200004)43:4<::AID-ANR12>3.0.CO;2-T.
65. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 94:8093-8. doi:10.1073/pnas.94.15.8093.
66. van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis (2000) 59(Suppl 1):i81-4. doi:10.1136/ard.59.suppl_1.i81.
67. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest (2001) 107:1519-27. doi:10.1172/JCI12724.
68. Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 13:235. doi:10.1186/ar3380.
69. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther (2008) 10:R104. doi:10.1186/ar2496.
70. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 365:2205-19. doi:10.7748/phc2011.11.21.9.29.c8797.
71. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol (1998) 152:943-51.
72. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum (2000) 43:250-8. doi:10.1002/1529-0131(200002)43:2<::AID-ANR3>3.0.CO;2-P.
73. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res (2009) 24:1572-85. doi:10.1359/jbmr.090320.
74. Klarenbeek NB, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Recent advances in the management of rheumatoid arthritis. BMJ (2010) 341:c6942. doi:10.1136/bmj.c6942.
75. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2004) 43(Suppl 3):iii17-23. doi:10.1093/rheumatology/keh203.
76. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther (2007) 9:R61. doi:10.1186/ar2219.
77. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum (1996) 39:797-809. doi:10.1002/art.1780390513.
78. Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum (2011) 63:2329-39. doi:10.1002/art.30418.
79. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest (2004) 114:582-8. doi:10.1172/JCI21795.
80. Matzelle MM, Gallant MA, Condon KW, Walsh NC, Manning CA, Stein GS. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum (2012) 64:1540-50. doi:10.1002/art.33504.
81. Asquith DL, Miller AM, McInnes IB, Liew FY. Animal models of rheumatoid arthritis. Eur J Immunol (2009) 39:2040-4. doi:10.1002/eji.200939578.
82. Frank S, Peters MA, Wehmeyer C, Strietholt S, Koers-Wunrau C, Bertrand J. Regulation of matrixmetalloproteinase-3 and matrixmetalloproteinase-13 by SUMO-2/3 through the transcription factor NF-kappaB. Ann Rheum Dis (2013) 72:1874-81. doi:10.1136/annrheumdis-2012-202080.
83. Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone (2001) 28:474-83. doi:10.1016/S8756-3282(01)00420-3.
84. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum (2001) 44:1003-12. doi:10.1002/1529-0131(200105)44:5<::AID-ANR179>3.3.CO;2-R.
85. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev (2010) 233:233-55. doi:10.1111/j.0105-2896.2009.00859.x.
86. Banfi G, Iorio EL, Corsi MM. Oxidative stress, free radicals and bone remodeling. Clin Chem Lab Med (2008) 46:1550-5. doi:10.1515/CCLM.2008.302.
87. Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol (2008) 26:73-80.
88. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol (2014) 57:28-37. doi:10.1016/j.molimm.2013.07.016.
89. Braun J, Sieper J. Ankylosing spondylitis. Lancet (2007) 369:1379-90. doi:10.1016/S0140-6736(07)60635-7.
90. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther (2009) 11:R127. doi:10.1186/ar2794.
91. Edwards CK III, Bendele AM, Reznikov LI, Fantuzzi G, Chlipala ES, Li L. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Arthritis Rheum (2006) 54:2872-85. doi:10.1002/art.22077.
92. van Duivenvoorde LM, Huriatul Masdar CAA, van Tok MN, Tak PP, Yeremenko NG, Baeten DL. A2.15 relative overexpression of transmembrane versus soluble TNF in human and experimental spondyloarthritis. Ann Rheum Dis (2013) 72:A9-10. doi:10.1136/annrheumdis-2013-203215.15.
93. Murariu RV, Macovei LA, Brujbu IC. Osteoporosis in rheumatoid arthritis. Rev Med Chir Soc Med Nat Iasi (2013) 117:394-403.
94. Okano T, Koike T, Tada M, Sugioka Y, Mamoto K, Wakitani S, et al. The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid. J Bone Miner Metab (2013). doi:10.1007/s00774-013-0535-9.
95. Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E. Osteoporosis in ankylosing spondylitis-prevalence, risk factors and methods of assessment. Arthritis Res Ther (2012) 14:R108. doi:10.1186/ar3833.
96. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science (2002) 296:1634-5. doi:10.1126/science.1071924.
97. Chakraborty C, Doss CG. Crucial protein based drug targets and potential inhibitors for osteoporosis: new hope and possibilities. Curr Drug Targets (2013) 14:1707-13. doi:10.2174/13894501113146660233.